Showing results (101-110 of 144) with videos related to
Sort By:
Pageof 15
BMJ Open Respiratory Research|May 21, 2024
Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort studyKieran J Rothnie, Robert P Wood, Alexandrosz Czira, et al.The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|February 24, 2022
Household air pollution and COPD: cause and effect or confounding by other aspects of poverty?K Mortimer, M Montes de Oca, S Salvi, et al.Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.ERJ Open Research|October 20, 2023
Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthmaJonathan Corren, Constance H Katelaris, Mario Castro, et al.The European Respiratory Journal|April 18, 2020
The effect of exacerbation history on outcomes in the IMPACT trialDavid M G Halpin, Mark T Dransfield, MeiLan K Han, et al.Respiratory Medicine|September 10, 2022
Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baselineArnaud Bourdin, J Christian Virchow, Alberto Papi, et al.Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 31, 2021
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT TrialByron Thomashow, Marjorie Stiegler, Gerard J Criner, et al.International Journal of Chronic Obstructive Pulmonary Disease|December 4, 2020
A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPDSimon Wan Yau Ming, John Haughney, Dermot Ryan, et al.The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|November 14, 2019
The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-income countriesD M G Halpin, B R Celli, G J Criner, et al.Pageof 15